The latest update is out from Australian Clinical Labs Ltd ( (AU:ACL) ).
Mitsubishi UFJ Financial Group, Inc. has ceased to be a substantial holder in Australian Clinical Labs Ltd as of early April 2025. This change in substantial holding, involving transactions with entities controlled by Morgan Stanley and First Sentier Investors Holdings Pty Ltd, may impact the company’s shareholder structure and influence its market dynamics.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates within the healthcare industry, primarily focusing on providing pathology services. The company serves a broad market, catering to both public and private healthcare sectors with a range of diagnostic testing services.
YTD Price Performance: -13.82%
Average Trading Volume: 911,278
Technical Sentiment Signal: Buy
Current Market Cap: A$582.3M
Learn more about ACL stock on TipRanks’ Stock Analysis page.